Erin Amjadi, MD
Internal Medicine · Austin, TXNPI 1871529115
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 319 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 14.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,250, 2.2 times the $575 reported in 2019. Among internal medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 319 payments — averaging $17.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$833
- GSK$640
- Novo Nordisk$534
- Pfizer$413
- Lilly USA, LLC$318
- Johnson & Johnson$315
- plus $3K from 28 others
What the payments were for
- Food & beverage$5,690100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 61 | $833 |
| GSK | 39 | $640 |
| Novo Nordisk | 29 | $534 |
| Pfizer | 23 | $413 |
| Lilly USA, LLC | 20 | $318 |
| Johnson & Johnson | 16 | $315 |
| Boehringer Ingelheim | 11 | $270 |
| Amgen | 14 | $241 |
| Sanofi-aventis U.S. LLC | 3 | $239 |
| AstraZeneca | 15 | $235 |
| Abbott | 10 | $218 |
| Astellas Pharma US Inc | 12 | $211 |
| Novartis | 8 | $132 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $124 |
| Amarin Pharma, Inc. | 7 | $114 |
| Bausch Health US, LLC | 6 | $108 |
| CMP Pharma, Inc. | 2 | $84 |
| Esperion Therapeutics, Inc. | 5 | $79 |
| Dexcom, Inc. | 3 | $77 |
| Merck | 4 | $74 |
| Medtronic | 3 | $70 |
| Noven Therapeutics, LLC | 3 | $63 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $49 |
| Xeris Pharmaceuticals, Inc. | 2 | $38 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $36 |
| Bayer | 2 | $34 |
| Lundbeck LLC | 1 | $23 |
| Exact Sciences | 1 | $22 |
| Cranial Technologies, Inc | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Genentech USA, Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $15 |
| Antares Pharma, Inc. | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PRALUENT$120
How this compares
$5,690 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 79 | $102,588 |
| MounjaroTirzepatide | 86 | $96,594 |
| JardianceEmpagliflozin | 58 | $66,040 |
| EliquisApixaban | 34 | $42,805 |
| FarxigaDapagliflozin Propanediol | 26 | $31,362 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $25,551 |
| XareltoRivaroxaban | 13 | $19,464 |
| RybelsusSemaglutide | 13 | $12,212 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $8,622 |
| Emgality PenGalcanezumab-Gnlm | 13 | $8,309 |
| Levothyroxine Sodium | 416 | $4,901 |
| SynthroidLevothyroxine Sodium | 69 | $4,092 |
| Nebivolol Hcl | 53 | $4,056 |
| Rosuvastatin Calcium | 298 | $4,037 |
| Advair DiskusFluticasone Propion/Salmeterol | 18 | $3,433 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $534 | $114,79992 claims |
| Lilly USA, LLCMounjaro | $318 | $96,59486 claims |
| Boehringer IngelheimJardiance | $270 | $66,04058 claims |
| PfizerEliquis, Paxlovid | $413 | $44,23451 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $640 | $34,17252 claims |
| AstraZenecaFarxiga | $235 | $31,36226 claims |
| Johnson & JohnsonXarelto | $315 | $19,46413 claims |
| AbbVieSynthroid, Armour Thyroid | $833 | $6,092102 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Austin
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Mohammed Al-NajjarEl Paso$586K
- Han SchmidlyDallas$465K
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
- Nitin JainHouston$281K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.